Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zynerba Pharmaceuticals's interest expense for the three months ended in Jun. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zynerba Pharmaceuticals's Operating Income for the three months ended in Jun. 2023 was $ -11.14 Mil. Zynerba Pharmaceuticals's Interest Expense for the three months ended in Jun. 2023 was $ 0.00 Mil. Zynerba Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Zynerba Pharmaceuticals Interest Expense Historical Data

The historical data trend for Zynerba Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals Interest Expense Chart

Zynerba Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

Zynerba Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Zynerba Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zynerba Pharmaceuticals (NAS:ZYNE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zynerba Pharmaceuticals's Interest Expense for the three months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2023 was $-11.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was $0.00 Mil.

Zynerba Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Zynerba Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Zynerba Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333

Website

http://www.zynerba.com

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Executives

Kenneth T Jones	officer: See Remarks	C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger	officer: VP, Commercial & Business Dev.	C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree	officer: President	ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher	officer: Chief Financial Officer	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido	director, officer: Chairman & Chief Exec. Officer	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch	director	68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper	director	NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson	director	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici	director	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker	officer: Chief Legal Officer	C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon	officer: Sec, General Counsel & VP HR	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp	10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison	director